Applicability of randomized controlled trials (RCTs) results to real-life patients in COPD Source: International Congress 2017 – Management of COPD Year: 2017
Augmentation therapy for α1 -antitrypsin deficiency: a meta-analysis of randomized and non-randomized clinical studies Source: Eur Respir J 2005; 26: Suppl. 49, 288s Year: 2005
Clinical effectiveness of MDI-HFA-Modulite budesonide in the treatment of asthma – meta-analysis of randomised controlled trials Source: Eur Respir J 2006; 28: Suppl. 50, 315s Year: 2006
Clinical effectiveness of MDI-HFA-Modulite beclomethasone in the treatment of asthma – meta-analysis of randomized controlled trials Source: Eur Respir J 2006; 28: Suppl. 50, 315s Year: 2006
Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19 Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19 Year: 2021
A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol Source: Eur Respir J 2016; 48: 320-330 Year: 2016
Systematic review of COPD re-exacerbation and exacerbation treatment failure definitions used in randomised controlled trials (RCTs) Source: International Congress 2018 – Epidemiology of COPD : from exarcebations and comorbidities to asthma-COPD overlap syndrome (ACOS) Year: 2018
Multidimensional assessment and targeted therapy of severe asthma: a randomised controlled trial (RCT) Source: International Congress 2017 – Many faces of asthma assessment Year: 2017
Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial Source: Eur Respir J, 54 (4) 1901030; 10.1183/13993003.01030-2019 Year: 2019
Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO) Source: ERJ Open Res, 8 (1) 00610-2021; 10.1183/23120541.00610-2021 Year: 2022
Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial. Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018
Helium-hyperoxia a novel treatment for optimizing pulmonary rehabilitation: a randomized controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 327s Year: 2007
RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations Source: Virtual Congress 2021 – ALERT: COPD Year: 2021
Efficacy and costs of telehealth for the management of COPD: PROMETE II, a multicentre, randomized controlled trial Source: International Congress 2017 – New trends in pulmonary rehabilitation and chronic care Year: 2017
PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017
Self-proning in COVID-19 patients on low-flow oxygen therapy. A cluster randomised controlled trial Source: Virtual Congress 2021 – COVID - 19 treatments Year: 2021
Mindfulness-based cognitive therapy in COPD: a cluster randomised controlled trial Source: Eur Respir J, 51 (2) 1702082; 10.1183/13993003.02082-2017 Year: 2018
The future of translational lung cancer research: from classical randomised controlled trials to innovative platform trials Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer Year: 2018
Outcomes reported in pneumonia randomized controlled trials Source: Virtual Congress 2021 – Pneumonia Year: 2021